MedKoo Cat#: 123388 | Name: RMC-6291
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Elironrasib, also known as RMC-6291 is an orally bioavailable, covalent KRAS G12C inhibitor. RMC-6291 forms a tri-complex with the intracellular chaperone protein and immunophilin cyclophilin A (CypA) and KRAS G12C(ON). This tri-complex inhibits KRAS G12C(ON)-mediated signaling, which may inhibit tumor cell proliferation. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Chemical Structure

RMC-6291
RMC-6291
CAS#2641998-63-0

Theoretical Analysis

MedKoo Cat#: 123388

Name: RMC-6291

CAS#: 2641998-63-0

Chemical Formula: C55H78FN9O8

Exact Mass: 1011.6000

Molecular Weight: 1012.28

Elemental Analysis: C, 65.26; H, 7.77; F, 1.88; N, 12.45; O, 12.64

Price and Availability

Size Price Availability Quantity
5mg USD 150.00 Ready to Ship
10mg USD 250.00 Ready to Ship
25mg USD 550.00 Ready to Ship
50mg USD 950.00 Ready to Ship
100mg USD 1,650.00 Ready to Ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RMC-6291; RMC6291; RMC 6291; GTPL12622; GTPL 12622; GTPL-12622; NSC851965; NSC 851965; NSC-851965; elironrasib
IUPAC/Chemical Name
1-(4-(dimethylamino)-4-methylpent-2-ynoyl)-N-((2S)-1-(((22S,63S,4S)-11-ethyl-12-(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-61,62,63,64,65,66-hexahydro-11H-8-oxa-2(4,2)-morpholina-1(5,3)-indola-6(1,3)-pyridazinacycloundecaphane-4-yl)amino)-3-methyl-1-oxobutan-2-yl)-4-fluoro-N-methylpiperidine-4-carboxamide
InChi Key
HJNFYLSFWYRSHS-CMZSUCOPSA-N
InChi Code
InChI=1S/C55H78FN9O8/c1-13-64-44-19-18-37-30-40(44)41(48(64)39-16-14-24-57-46(39)36(4)71-12)32-53(5,6)34-73-51(69)42-17-15-25-65(59-42)50(68)43(31-38-33-63(37)28-29-72-38)58-49(67)47(35(2)3)61(11)52(70)55(56)22-26-62(27-23-55)45(66)20-21-54(7,8)60(9)10/h14,16,18-19,24,30,35-36,38,42-43,47,59H,13,15,17,22-23,25-29,31-34H2,1-12H3,(H,58,67)/t36-,38-,42-,43-,47-/m0/s1
SMILES Code
C[C@@H](C1=[C@]([C@](N2CC)=C(C3=C2C=CC4=C3)CC(C)(COC([C@H]5NN(CCC5)C([C@H](C[C@H]6CN4CCO6)NC([C@@H](N(C)C(C7(CCN(CC7)C(C#CC(C)(C)N(C)C)=O)F)=O)C(C)C)=O)=O)=O)C)C=CC=N1)OC
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Certificate of Analysis
Safety Data Sheet (SDS)

Preparing Stock Solutions

The following data is based on the product molecular weight 1,012.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Nokin MJ, Mira A, Patrucco E, Ricciuti B, Cousin S, Soubeyran I, San José S, Peirone S, Caizzi L, Vietti Michelina S, Bourdon A, Wang X, Alvarez-Villanueva D, Martínez-Iniesta M, Vidal A, Rodrigues T, García-Macías C, Awad MM, Nadal E, Villanueva A, Italiano A, Cereda M, Santamaría D, Ambrogio C. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nat Commun. 2024 Aug 30;15(1):7554. doi: 10.1038/s41467-024-51828-2. PMID: 39215000; PMCID: PMC11364849.